Close

Anrukinzumab (= IMA-638) (TAB-252)

DESCRIPTION CATALOG # SIZE PRICE
Anti-Human ITGA3 Therapeutic Antibody TAB-252 1mg Please Inquiry

PRODUCT INFORMATION

  • Product Overview
  • Recombinant monoclonal antibody to ITGA3. Anrukinzumab (IMA-638) is a humanized monoclonal antibody designed for the treatment of asthma.
  • Target
  • IL-13
  • Type
  • Humanized (from mouse) IgG1 Kappa
  • Immunogen
  • Recombinant full length protein (Human).
  • Species Reactivity
  • Human
  • Expression Host
  • CHO
  • Applications
  • Suitable for use in WB, Neut, ELISA, IF, IP, FuncS, FC and most other immunological methods.
  • CAS
  • 910649-32-0
  • Specificity
  • Tested positive against native human antigen.
  • Protein Construction
  • Immunoglobulin G1, anti-(human CD40 (antigen)) (human-mouse monoclonal SGN-40 γ1-chain), disulfide with human-mouse monoclonal SGN-40 Kappa-chain, dimer
  • Predicted N terminal
  • H chain: EVQLVES; L chain: DIQMTQS
  • Molecular Weight
  • 145400
  • Purity
  • Purity >95% by SDS-PAGE.
  • Size
  • 1mg
  • Storage
  • Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.

BACKGROUND

  • Antigen Description
  • Cytokine. Inhibits inflammatory cytokine production. Synergizes with IL2 in regulating interferon-gamma synthesis. May be critical in regulating inflammatory and immune responses.
  • Function
  • cytokine activity; interleukin-13 receptor binding; protein binding;
  • Synonyms
  • IL13; interleukin 13; interleukin-13; allergic rhinitis; ALRH; BHR1; Bronchial hyperresponsiveness 1 (bronchial asthma); IL 13; MGC116786; MGC116788; MGC116789; P600; Bronchial hyperresponsiveness-1 (bronchial asthma); IL-13;

Related Products

Online Inquiry

Verification code
Click image to refresh the verification code.

CONTACT US

45-1 Ramsey Road, Shirley, NY 11967, USA
Call us at:
USA: 1-631-381-2994
Europe: 44-207-097-1828
Fax: 1-631-207-8356
Email:
Our customer service representatives are available 24 hours a day, 7 days a week. Contact Us